Persistent URL of this record https://hdl.handle.net/1887/85270
Documents
-
- Download
- Clinical_Infectious_Diseases_2019_Knibbe
- Publisher's Version
- open access
- Full text at publishers site
In Collections
This item can be found in the following collections:
Fixed dosing of liposomal Amphotericin B in morbidly obese individuals
Abstract
In this prospective study, we examined the pharmacokinetics of 1 and 2 mg/kg liposomal amphotericin B in 16 morbidly obese individuals (104–177 kg). Body size had no effect on clearance. We recommend a fixed dose in patients ≥100 kg (ie, 300 or 500 mg rather than the current dose of 3 and 5 mg/kg, respectively).
Clinical Trials Registration NCT02320604.
- All authors
- Wasmann, R.E.; Smit, C.; Dongen, E.P.H. van; Wiezer, R.M.J.; Adler-Moore, J.; Beer, Y.M. de; Burger, D.M.; Knibbe, C.A.J.; Bruggemann, R.J.M.
- Date
- 2019-10-07
- Journal
- Clinical Infectious Diseases
- Volume
- 70
- Issue
- 10
- Pages
- 2213 - 2215